Camber Capital Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-800,000
| Closed | -$51.1M | – | 34 |
|
|
2025
Q1 | $51.1M | Sell |
800,000
-200,000
| -20% | -$21.1M | 1.81% | 15 |
|
|
2024
Q4 | $122M | Buy |
1,000,000
+225,000
| +29% | +$27.6M | 2.81% | 13 |
|
|
2024
Q3 | $96.8M | Buy |
775,000
+625,000
| +417% | +$86.4M | 3.07% | 12 |
|
|
2024
Q2 | $23.7M | Sell |
150,000
-435,000
| -74% | -$55.9M | 0.66% | 25 |
|
|
2024
Q1 | $75.7M | Sell |
585,000
-215,000
| -27% | -$26.3M | 1.86% | 17 |
|
|
2023
Q4 | $77.1M | Hold |
800,000
| – | – | 1.97% | 17 |
|
|
2023
Q3 | $97M | Buy |
800,000
+400,000
| +100% | +$45.2M | 3.2% | 14 |
|
|
2023
Q2 | $45.8M | Sell |
400,000
-350,000
| -47% | -$45.1M | 1.49% | 21 |
|
|
2023
Q1 | $103M | Sell |
750,000
-500,000
| -40% | -$64.9M | 3.18% | 13 |
|
|
2022
Q4 | $162M | Sell |
1,250,000
-250,000
| -17% | -$29M | 5.56% | 6 |
|
|
2022
Q3 | $166M | Sell |
1,500,000
-350,000
| -19% | -$35.3M | 5.08% | 4 |
|
|
2022
Q2 | $139M | Buy |
1,850,000
+475,000
| +35% | +$34.9M | 6.02% | 4 |
|
|
2022
Q1 | $107M | Buy |
1,375,000
+550,000
| +67% | +$42.1M | 3.89% | 11 |
|
|
2021
Q4 | $74.3M | Buy |
825,000
+325,000
| +65% | +$27.8M | 2.55% | 19 |
|
|
2021
Q3 | $46.2M | Buy |
+500,000
| New | +$38.5M | 1.42% | 29 |
|
|
2021
Q1 | – | Sell |
-400,000
| Closed | -$68.2M | – | 41 |
|
|
2020
Q4 | $68.2M | Sell |
400,000
-25,000
| -6% | -$3.7M | 2.39% | 17 |
|
|
2020
Q3 | $59.7M | Buy |
425,000
+25,000
| +6% | +$3.8M | 3.15% | 11 |
|
|
2020
Q2 | $64.1M | Sell |
400,000
-325,000
| -45% | -$44.2M | 3.67% | 11 |
|
|
2020
Q1 | $70.9M | Buy |
725,000
+125,000
| +21% | +$14.3M | 4.23% | 11 |
|
|
2019
Q4 | $77.4M | Sell |
600,000
-150,000
| -20% | -$15.1M | 3.94% | 12 |
|
|
2019
Q3 | $56.5M | Buy |
750,000
+250,000
| +50% | +$29.5M | 2.97% | 16 |
|
|
2019
Q2 | $76M | Hold |
500,000
| – | – | 3.54% | 11 |
|
|
2019
Q1 | $59.6M | Buy |
500,000
+150,000
| +43% | +$19.3M | 2.97% | 14 |
|
|
2018
Q4 | $38.2M | Buy |
+350,000
| New | +$43.8M | 1.81% | 24 |
|
|
2018
Q1 | – | Sell |
-300,000
| Closed | -$16.7M | – | 38 |
|
|
2017
Q4 | $16.7M | Sell |
300,000
-1,100,000
| -79% | -$58.3M | 0.82% | 26 |
|
|
2017
Q3 | $63.5M | Buy |
1,400,000
+100,000
| +8% | +$4M | 4.02% | 11 |
|
|
2017
Q2 | $43.8M | Sell |
1,300,000
-50,000
| -4% | -$1.63M | 2.13% | 16 |
|
|
2017
Q1 | $40M | Buy |
+1,350,000
| New | +$41.8M | 1.62% | 22 |
|
|
2013
Q4 | – | Sell |
-500,000
| Closed | -$23.6M | – | 39 |
|
|
2013
Q3 | $23.6M | Buy |
+500,000
| New | +$19.3M | 2.48% | 18 |
|
Other funds holding SRPT
EAM
Camber Capital Management's SRPT Position: Q2 2025 in Review
Camber Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 800,000 shares — an estimated $51.1M sold.
Camber Capital Management first reported a position in SRPT in Q3 2013 and held it in 29 quarters. The position peaked at $166M in Q3 2022. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- Camber Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- Camber Capital Management sold 800,000 Sarepta Therapeutics shares in Q2 2025, an estimated $51.1M.
- Camber Capital Management first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 29 quarters.
- Camber Capital Management's Sarepta Therapeutics position peaked at $166M in Q3 2022.
- 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.